Year end report 1998

Report this content

Year end report 1998 Continued good growth * Revenues amounted to 18,734 MSEK (19,490), an increase by 25% for present structure incl. acquisitions. * ings after financial items amounted to SEK 4,991 M (13,890), incl. non- recurring items of SEK 4,179 M (12,949). * ntinued expansion and good growth for Renal Care Services. Good growth for Renal Care Products and Blood Component Technology. Stable development in Cardiovascular Care. In total a weaker earnings/margin development. * Strategic streamlining into medical technology and healthcare completed during 1998. Agreement on divestiture of the Cardiovascular Care operations. * The Board of Directors proposes a dividend of SEK 1.00 (2.00), a change in accordance with the new dividend policy which complies with the new orientation of the group. * January 1999: Major restructuring and efficiency improvement program launched. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, +46-8-613 65 00, +46-70-513 65 33 Lars Granlöf, Vice President, Corporate Control, +46-8-613 65 00 Anna Augustson, European Investor Relations Manager, +46-8-613 65 00 Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185 ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/02/24/19990224BIT00180/bit0001.doc The full report http://www.bit.se/bitonline/1999/02/24/19990224BIT00180/bit0002.pdf The full report

Documents & Links